About Isabl
Isabl is a company based in New York (United States) founded in 2020 by Juan Medina, Andrew Kung, and Elli Papaemmanuil. Isabl has raised $3 million across 2 funding rounds from investors including HHS, Box 1 and Evolution VC Partners. The company has 3 employees as of December 31, 2024. Isabl offers products and services including Isabl GxT and WGTS SaaS. Isabl operates in a competitive market with competitors including Denali Therapeutics, Strand Life Sciences, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
- Headquarter New York, United States
- Employees 3 as on 31 Dec, 2024
- Founders Juan Medina, Andrew Kung, Elli Papaemmanuil
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Isabl Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 2 rounds
-
Latest Funding Round
$2.03 M (USD), Grant
Apr 01, 2023
-
Investors
HHS
& 6 more
-
Employee Count
3
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Isabl
Isabl offers a comprehensive portfolio of products and services, including Isabl GxT and WGTS SaaS.
Analyzes entire tumor genome and transcriptome for cancer mutation detection
Platform for whole genome tumor sequencing services in cancer care
People of Isabl
Unlock access to complete
Unlock access to complete
Funding Insights of Isabl
Isabl has successfully raised a total of $3M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $2.03 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Isabl
Isabl has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, Box 1 and Evolution VC Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in tech startups are made by Evolution VC Partners.
|
Locked | Locked | Locked | |
|
Angel funding is provided to Silicon Valley-based companies.
|
Locked | Locked | Locked | |
|
Early-stage investments in tech sectors are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Isabl
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Isabl
Investment portfolio details for Isabl
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Isabl
Detailed financials for Isabl
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Isabl Comparisons
Peer comparison for Isabl
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Isabl
Isabl operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Strand Life Sciences, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Detailed competitors of Isabl
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Isabl
Complete news archive for Isabl
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Isabl
Isabl was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Isabl is headquartered in New York, United States. It is registered at New York, New York, United States.
Elli Papaemmanuil is the current CEO of Isabl. They have also founded this company.
Isabl is a funded company, having raised a total of $3M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Isabl is 3.
Isabl was founded in 2020 in New York, United States, within the healthcare technology sector. A platform for medical diagnosis is developed to examine genomes of cancer patients. The Isabl GxT platform is utilized to assess both genome and transcriptome data, enabling identification of mutations, disease monitoring, and biomarker detection. Operations focus on genomic analysis services for oncology applications.
Isabl's top competitors include Strand Life Sciences, Juno Therapeutics and Personalis.
Isabl offers Isabl GxT and WGTS SaaS.
Isabl has 7 investors. Key investors include HHS, Box 1, Evolution VC Partners, Milad Alucozai, and Sand Hill Angels.